Posts

Showing posts from April, 2020

Cell Line Development Market Rising Demand for Digitization in Organizations and Growth till 2027

Image
The growth of the is driven by the factors such as increase in the demand for innovative products from biopharmaceutical and biotechnology companies, the presence of key market players, and extensive R&D conducted by various academic and research institutes in the North America region. The medical biotechnology has undergone revolutions as a result of various development programs, business strategies that helps to produce, discover, or alter various biomolecules and organisms through bioengineering approaches. The Biotech Startup Revolution has also assisted in promoting the new ventures holding promising and innovative ideas in the country and supported in maximizing the revenue generation and thus the economic position of North America in the global cell line development market. Register for a free Trial today and gain instant*access @ Click Here Top Dominating Key Players: Merck KGaA Thermo Fisher Scientific, Inc. Sartorius AG SELEXIS BioFactura, Inc. WuXi AppT

Better Opportunities for Oncology Biosimilars

Image
Biosimilars are the fastest-growing class of therapeutic products across the globe. Biosimilars are biologics that serves as interchangeable products offering additional treatment options to a branded drug counterpart, potentially reducing the cost of the prescribed biologics. The biosimilar therapies have been for chronic disease management and supportive care since a few years, however the use of these biosimilars are expected to be applied soon for treatment of various types of cancers referred to as oncology biosimilars. Get PDF Sample Copy of this Report !!! The market for oncology biosimilars market is expected to witness growth due to extensive research undertaken by market players to bring biosimilars for cancer treatment in the market as well as rapid approval by regulatory authorities for commercialization of these products. However, high costs involved in the research and complexity involved in the formulation of these biologics are likely to hinder market growth.